You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 769 Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
769 Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to November 2024

AbstractFullPdf
Nov 2022584051
Dec 2022231021
Jan 2023132010
Feb 2023192012
Mar 2023182011
Apr 20235407
May 20235806
Jun 20234506
Jul 202374011
Aug 20234304
Sep 20235805
Oct 20234002
Nov 20235607
Dec 202311609
Jan 20243803
Feb 202419202
Mar 20246005
Apr 202467010
May 20243006
Jun 20241801
Jul 20242001
Aug 20243409
Sep 20243204
Oct 20242609
Nov 20243805
Total24200217